110 related articles for article (PubMed ID: 2104076)
1. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
Morgan MY; Stambuk D; Cottrell J; Mann SG
Aliment Pharmacol Ther; 1990 Feb; 4(1):83-96. PubMed ID: 2104076
[TBL] [Abstract][Full Text] [Related]
2. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of famotidine in patients with cirrhosis and ascites.
Vinçon G; Baldit C; Couzigou P; Demotes-Mainard F; Elouaer-Blanc L; Bannwarth B; Begaud B
Eur J Clin Pharmacol; 1992; 43(5):559-62. PubMed ID: 1483496
[TBL] [Abstract][Full Text] [Related]
5. Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
Ohnishi K
Hepatogastroenterology; 1990 Jul; 37 Suppl 1():6-10. PubMed ID: 2210613
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of famotidine in infants.
Wenning LA; Murphy MG; James LP; Blumer JL; Marshall JD; Baier J; Scheimann AO; Panebianco DL; Zhong L; Eisenhandler R; Yeh KC; Kearns GL
Clin Pharmacokinet; 2005; 44(4):395-406. PubMed ID: 15828852
[TBL] [Abstract][Full Text] [Related]
7. Effect of famotidine on ciprofloxacin pharmacokinetics after single intravenous and oral doses in rats.
al-Khamis KI; Jim LK; Bawazir SA; Ashour LF; el-Sayed N; el-Sayed YM
J Clin Pharm Ther; 1994 Dec; 19(6):335-9. PubMed ID: 7876363
[TBL] [Abstract][Full Text] [Related]
8. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
[TBL] [Abstract][Full Text] [Related]
9. Enhanced oral bioavailability of meptazinol in cirrhosis.
Birnie GG; Thompson GG; Murray T; Watkinson G; Brodie MJ
Gut; 1987 Mar; 28(3):248-54. PubMed ID: 3570028
[TBL] [Abstract][Full Text] [Related]
10. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
Pentikäinen PJ; Välisalmi L; Himberg JJ; Crevoisier C
J Clin Pharmacol; 1989 Mar; 29(3):272-7. PubMed ID: 2723115
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.
Hayton WL; Kneer J; Blouin RA; Stoeckel K
Antimicrob Agents Chemother; 1990 Jul; 34(7):1318-22. PubMed ID: 2386364
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
Nagita A; Manago M; Aoki S; Mino M; Suzuki K; Ashida K
Ther Drug Monit; 1994 Oct; 16(5):444-9. PubMed ID: 7846741
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and elimination of nitrendipine in liver disease.
Dylewicz P; Kirch W; Santos SR; Hutt HJ; Mönig H; Ohnhaus EE
Eur J Clin Pharmacol; 1987; 32(6):563-8. PubMed ID: 3653225
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.
Andersson T; Olsson R; Regårdh CG; Skånberg I
Clin Pharmacokinet; 1993 Jan; 24(1):71-8. PubMed ID: 8448974
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
Gladziwa U; Wagner S; Dakshinamurty KV; el Desoky E; Dreuw B; Klotz U
Eur J Clin Pharmacol; 1993; 44(4):357-60. PubMed ID: 8513846
[TBL] [Abstract][Full Text] [Related]
18. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.
van Harten J; van Brummelen P; Wilson JH; Lodewijks MT; Breimer DD
Eur J Clin Pharmacol; 1988; 34(4):387-94. PubMed ID: 3402524
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of octreotide in cirrhosis and in healthy man.
Ottesen LH; Flyvbjerg A; Jakobsen P; Bendtsen F
J Hepatol; 1997 May; 26(5):1018-25. PubMed ID: 9186832
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
